EP0842925A1
(en)
*
|
1987-09-04 |
1998-05-20 |
Beecham Group Plc |
Substituted thiazolidinedione derivatives
|
US5232925A
(en)
*
|
1987-09-04 |
1993-08-03 |
Beecham Group P.L.C. |
Compounds
|
US5194443A
(en)
*
|
1987-09-04 |
1993-03-16 |
Beecham Group P.L.C. |
Compounds
|
GB8820389D0
(en)
*
|
1988-08-26 |
1988-09-28 |
Beecham Group Plc |
Novel compounds
|
GB8919417D0
(en)
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
GB8919434D0
(en)
*
|
1989-08-25 |
1989-10-11 |
Beecham Group Plc |
Novel compounds
|
US5053420A
(en)
*
|
1989-10-13 |
1991-10-01 |
Pershadsingh Harrihar A |
Thiazolidine derivatives for the treatment of hypertension
|
US5037842A
(en)
*
|
1990-06-05 |
1991-08-06 |
Pfizer Inc. |
Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
|
GB9017218D0
(en)
*
|
1990-08-06 |
1990-09-19 |
Beecham Group Plc |
Novel compounds
|
GB9023584D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
GB9023583D0
(en)
*
|
1990-10-30 |
1990-12-12 |
Beecham Group Plc |
Novel compounds
|
DE69214467T3
(de)
*
|
1991-01-10 |
2000-09-28 |
Transcend Therapeutics, Inc. |
Verwendung von L-2-oxo Thiazolidin-4-carboxylat zur Behandlung von Atemnotsyndrom
|
US5747459A
(en)
*
|
1991-02-04 |
1998-05-05 |
Nestec, Ltd. |
Method for insuring adequate intracellular glutathione in tissue
|
JP3053490B2
(ja)
*
|
1991-02-25 |
2000-06-19 |
杏林製薬株式会社 |
チアゾリジン−2,4−ジオン誘導体とその塩及び製造法
|
GB9124513D0
(en)
*
|
1991-11-19 |
1992-01-08 |
Smithkline Beecham Plc |
Novel process
|
NO179246C
(no)
*
|
1991-11-20 |
1996-09-04 |
Sankyo Co |
Aromatiske amino-alkoholderivater og mellomprodukter til fremstilling derav
|
US5589492A
(en)
*
|
1992-04-10 |
1996-12-31 |
Smithkline Beecham Plc |
Heterocyclic compounds and their use in the treatment of Type-II diabetes
|
JPH07505647A
(ja)
*
|
1992-04-10 |
1995-06-22 |
スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー |
複素環化合物および2型糖尿病の治療におけるそれらの使用
|
US5430045A
(en)
*
|
1992-04-23 |
1995-07-04 |
Free Radical Sciences, Inc. |
Method of reducing or preventing bone marrow hypoplasia
|
AU678974B2
(en)
*
|
1992-07-03 |
1997-06-19 |
Smithkline Beecham Plc |
Heterocyclic compounds as pharmaceutical
|
US5326770A
(en)
*
|
1992-07-17 |
1994-07-05 |
The Du Pont Merck Pharmaceutical Company |
Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
|
US5306724A
(en)
*
|
1992-08-17 |
1994-04-26 |
Clintec Nutrition Company |
Method for preventing and treating atherosclerosis
|
ATE185564T1
(de)
*
|
1992-08-31 |
1999-10-15 |
Sankyo Co |
Oxazolidin-derivate mit antidiabetika und anti- fettleibigkeit-eigenschaften, ihre herstellung und therapeutische verwendung
|
GB9218830D0
(en)
*
|
1992-09-05 |
1992-10-21 |
Smithkline Beecham Plc |
Novel compounds
|
US5741803A
(en)
*
|
1992-09-05 |
1998-04-21 |
Smithkline Beecham Plc |
Substituted thiazolidinedionle derivatives
|
EP0645387A1
(en)
*
|
1993-04-07 |
1995-03-29 |
Taiho Pharmaceutical Co., Ltd. |
Thiazolidine derivative and pharmaceutical composition containing the same
|
GB9308487D0
(en)
*
|
1993-04-23 |
1993-06-09 |
Smithkline Beecham Plc |
Novel compounds
|
GB9311644D0
(en)
*
|
1993-06-05 |
1993-07-21 |
Smithkline Beecham Plc |
Novel compounds
|
GB9311661D0
(en)
*
|
1993-06-05 |
1993-07-21 |
Smithkline Beecham Plc |
Novel compounds
|
GB9315148D0
(en)
*
|
1993-07-22 |
1993-09-08 |
Smithkline Beecham Plc |
Novel compounds
|
USRE39384E1
(en)
|
1993-09-01 |
2006-11-07 |
Smithkline Beecham P.L.C. |
Substituted thiazolidinedione derivatives
|
DK0719140T3
(da)
*
|
1993-09-15 |
2008-03-03 |
Daiichi Sankyo Co Ltd |
Anvendelse af thiazolidindioner til forebyggelse eller forsinkelse af indtræden af NIDDM
|
US5478852C1
(en)
*
|
1993-09-15 |
2001-03-13 |
Sankyo Co |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
|
US5874454A
(en)
*
|
1993-09-15 |
1999-02-23 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US6046222A
(en)
*
|
1993-09-15 |
2000-04-04 |
Warner-Lambert Company |
Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus
|
US5447712A
(en)
*
|
1993-12-09 |
1995-09-05 |
Free Radical Sciences |
Method of reducing cyclophosphamide induced hemorrhagic cystitis
|
US5480896A
(en)
*
|
1994-01-27 |
1996-01-02 |
American Home Products Corporation |
Aralkyl-1,2,4-oxadiazolidine-3,5-diones as antihyperglycemic agents
|
SG47100A1
(en)
*
|
1994-02-10 |
1998-03-20 |
Smithkline Beecham Plc |
Use of insulin sensitisers for treating renal diseases
|
NO305987B1
(no)
*
|
1994-04-11 |
1999-08-30 |
Sankyo Co |
Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
|
US5594015A
(en)
*
|
1994-06-22 |
1997-01-14 |
Regents Of The University Of California |
Thiazolidine derivatives for the treatment of psoriasis
|
US5703096A
(en)
|
1994-10-07 |
1997-12-30 |
Sankyo Company, Limited |
Oxime derivatives, their preparation and their therapeutic use
|
US5436373A
(en)
*
|
1994-10-26 |
1995-07-25 |
Elf Atochem North America, Inc. |
Process for the preparation of N-benzyl-N-organoaminoalkanol
|
US5641796A
(en)
*
|
1994-11-01 |
1997-06-24 |
Eli Lilly And Company |
Oral hypoglycemic agents
|
US5827865A
(en)
*
|
1995-03-09 |
1998-10-27 |
Smithkline Beecham P.L.C. |
Heterocyclic compounds as pharmaceutical
|
US5925656A
(en)
*
|
1995-04-10 |
1999-07-20 |
Dr. Reddy's Research Foundation |
Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5708012A
(en)
*
|
1995-04-28 |
1998-01-13 |
Sankyo Company, Limited |
Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of insulin resistant subjects with normal glucose tolerance in order to prevent or delay the onset of noninsulin-dependent mellitus
|
IL118474A
(en)
*
|
1995-06-01 |
2001-08-08 |
Sankyo Co |
Benzimideol derivatives and pharmaceutical preparations containing them
|
TWI238064B
(en)
|
1995-06-20 |
2005-08-21 |
Takeda Chemical Industries Ltd |
A pharmaceutical composition for prophylaxis and treatment of diabetes
|
US5798375A
(en)
*
|
1995-07-03 |
1998-08-25 |
Sankyo Company, Limited |
Treatment of arteriosclerosis and xanthoma
|
US6090836A
(en)
*
|
1996-02-02 |
2000-07-18 |
Merck & Co., Inc. |
Benzisoxazole-derived antidiabetic compounds
|
US6020382A
(en)
*
|
1996-02-02 |
2000-02-01 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
US5847008A
(en)
*
|
1996-02-02 |
1998-12-08 |
Merck & Co., Inc. |
Method of treating diabetes and related disease states
|
US5859051A
(en)
*
|
1996-02-02 |
1999-01-12 |
Merck & Co., Inc. |
Antidiabetic agents
|
IL120443A
(en)
*
|
1996-03-18 |
2000-07-16 |
Sankyo Co |
Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
|
NZ332136A
(en)
*
|
1996-04-04 |
1999-08-30 |
Sankyo Co |
Phenylalkylcarboxylic acid derivatives useful for treating hyperglycemia
|
ATE231136T1
(de)
*
|
1996-04-09 |
2003-02-15 |
Reddys Lab Ltd Dr |
Thiazolidinedionderivate mit antidiabetischen, hypolipidämischen und antihypertensiven eigenschaften, verfahren zu deren herstellung und pharmazeutischen zusammenstellungen, die sie enthalten
|
US5889032A
(en)
*
|
1996-05-06 |
1999-03-30 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US5919782A
(en)
*
|
1996-05-06 |
1999-07-06 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
ZA973850B
(en)
*
|
1996-05-06 |
1997-12-02 |
Reddy Research Foundation |
Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
|
US5801173A
(en)
*
|
1996-05-06 |
1998-09-01 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
WO1997043283A1
(de)
*
|
1996-05-16 |
1997-11-20 |
Boehringer Mannheim Gmbh |
Neues verfahren zur herstellung von troglitazone
|
CA2257284C
(en)
*
|
1996-05-31 |
2005-10-04 |
Sankyo Company Limited |
Remedy for autoimmune diseases
|
US6372750B2
(en)
|
1996-07-01 |
2002-04-16 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases
|
USRE39266E1
(en)
*
|
1996-07-01 |
2006-09-05 |
Dr. Reddy's Laboratories, Limited |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
US6114526A
(en)
*
|
1996-07-01 |
2000-09-05 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
KR100579765B1
(ko)
*
|
1996-07-01 |
2006-12-28 |
닥터 레디스 레보러터리즈 리미티드 |
신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
|
US5885997A
(en)
*
|
1996-07-01 |
1999-03-23 |
Dr. Reddy's Research Foundation |
Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
|
WO1997041120A1
(en)
*
|
1996-07-26 |
1997-11-06 |
Dr. Reddy's Research Foundation |
Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
|
US6090839A
(en)
*
|
1996-12-23 |
2000-07-18 |
Merck & Co., Inc. |
Antidiabetic agents
|
US6160000A
(en)
*
|
1996-12-23 |
2000-12-12 |
Merck & Co., Inc. |
Antidiabetic agents based on aryl and heteroarylacetic acids
|
UY24886A1
(es)
*
|
1997-02-18 |
2001-08-27 |
Smithkline Beecham Plc |
Tiazolidindiona
|
AU774839B2
(en)
*
|
1997-02-18 |
2004-07-08 |
Smithkline Beecham Plc |
Process for the preparation of substituted thiazolidinedione
|
CA2323889A1
(en)
*
|
1997-03-12 |
1998-09-17 |
Robert W. Esmond |
A method for treating or preventing alzheimer's disease
|
DE19711616A1
(de)
*
|
1997-03-20 |
1998-09-24 |
Boehringer Mannheim Gmbh |
Verbessertes Verfahren zur Herstellung von Thiazolidindionen
|
US6313113B1
(en)
|
1997-04-15 |
2001-11-06 |
Reddy-Cheminor, Inc. |
Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
|
US6011031A
(en)
*
|
1997-05-30 |
2000-01-04 |
Dr. Reddy's Research Foundation |
Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
|
GB9711683D0
(en)
*
|
1997-06-05 |
1997-08-06 |
Smithkline Beecham Plc |
Composition
|
CZ298469B6
(cs)
*
|
1997-06-18 |
2007-10-10 |
Smithkline Beecham Plc |
Farmaceutický prostredek obsahující 5-[4-/2-(N-methyl-N-(2-pyridyl)amino)ethoxy/benzyl]thiazolidin-2,4-dion a metformin, a lécivo pro lécení diabetesmellitus
|
PL337510A1
(en)
*
|
1997-06-18 |
2000-08-28 |
Smithkline Beecham Plc |
Treatment of diabetes by means of derivatives of thiazolydinone and sulphonylurea
|
GB9715306D0
(en)
*
|
1997-07-18 |
1997-09-24 |
Smithkline Beecham Plc |
Novel method of treatment
|
CA2305808A1
(en)
|
1997-10-02 |
1999-04-15 |
Sankyo Company Limited |
Amidocarboxylic acid derivatives
|
GB9721693D0
(en)
*
|
1997-10-13 |
1997-12-10 |
Smithkline Beecham Plc |
Novel treatment
|
GB9721692D0
(en)
*
|
1997-10-13 |
1997-12-10 |
Smithkline Beecham Plc |
Novel treatment
|
US20010031776A1
(en)
*
|
1997-10-13 |
2001-10-18 |
Smithkline Beecham P.L.C. |
Use of thiazolidinediones for the treatment of hyperglycaemia
|
US20020006939A1
(en)
*
|
1997-10-13 |
2002-01-17 |
Smithkline Beecham P.L.C. |
Use of thiazolidinediones for the treatment of hyperglycaemia
|
US7091359B2
(en)
|
1997-11-04 |
2006-08-15 |
Smithkline Beecham Plc |
Process for the preparation of thiazolidinedione derivatives
|
GB9723295D0
(en)
*
|
1997-11-04 |
1998-01-07 |
Smithkline Beecham Plc |
Novel process
|
HUP9902721A2
(hu)
|
1997-11-25 |
1999-12-28 |
The Procter & Gamble Co. |
Tömény textillágyító készítmény és ehhez alkalmazható magas telítetlenségű textillágyító vegyület
|
WO1998045291A1
(en)
*
|
1997-12-02 |
1998-10-15 |
Dr. Reddy's Research Foundation |
Substituted thiazolidinedione and oxazolidinedione having antidiabetic, hypolipidemia and antihypertensive properties
|
AU6966498A
(en)
*
|
1997-12-02 |
1998-10-30 |
Dr. Reddy's Research Foundation |
Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypol ipidaemic and antihypertensive properties
|
US20020137940A1
(en)
*
|
1997-12-16 |
2002-09-26 |
Smithkline Beecham P.L.C. |
5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
|
GB9726568D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US6664278B2
(en)
|
1997-12-16 |
2003-12-16 |
Smithkline Beecham P.L.C. |
Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
|
WO1999030739A1
(fr)
*
|
1997-12-16 |
1999-06-24 |
Sankyo Company, Limited |
Remede contre la leucemie
|
GB9726563D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB9726566D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US20040058873A1
(en)
*
|
1998-03-12 |
2004-03-25 |
Esmond Robert W. |
Method for treating or preventing Alzheimer's disease
|
US7045519B2
(en)
*
|
1998-06-19 |
2006-05-16 |
Chiron Corporation |
Inhibitors of glycogen synthase kinase 3
|
CN1312807A
(zh)
|
1998-06-19 |
2001-09-12 |
希龙公司 |
糖元合成酶激酶3的抑制剂
|
MA26662A1
(fr)
*
|
1998-07-21 |
2004-12-20 |
Smithkline Beecham Plc |
Derives de thiazolidinedione, compositions pharmaceutiques les contenant et leur utilisation
|
US6613785B2
(en)
|
1998-07-21 |
2003-09-02 |
Smithkline Beecham Plc |
Use of glucose uptake enhancer for reducing post-ischemic injury of the heart
|
EA200100165A1
(ru)
*
|
1998-07-21 |
2001-08-27 |
Смитклайн Бичам Плс |
Применение усилителя захвата глюкозы для уменьшения апоптоза
|
IN187716B
(pt)
*
|
1998-09-14 |
2002-06-15 |
Reddy Research Foundation |
|
US20040081697A1
(en)
*
|
1998-11-12 |
2004-04-29 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
GB9824893D0
(en)
*
|
1998-11-12 |
1999-01-06 |
Smithkline Beckman Corp |
Novel method of treatment
|
US20030153607A1
(en)
*
|
1998-11-12 |
2003-08-14 |
Smithkline Beecham P.L.C. |
Novel composition and use
|
CA2351058A1
(en)
|
1998-11-12 |
2000-05-25 |
Smithkline Beecham P.L.C. |
Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
|
US20040102486A1
(en)
*
|
1998-11-12 |
2004-05-27 |
Smithkline Beecham Corporation |
Novel method of treatment
|
DZ2937A1
(fr)
|
1998-11-12 |
2004-03-15 |
Smithkline Beecham Plc |
Compositions nouvelles de sensibilidants à l'insuline.
|
CA2350599A1
(en)
*
|
1998-11-20 |
2000-06-02 |
Genentech, Inc. |
Method of inhibiting angiogenesis
|
US6191154B1
(en)
|
1998-11-27 |
2001-02-20 |
Case Western Reserve University |
Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
|
WO2000043006A1
(fr)
*
|
1999-01-19 |
2000-07-27 |
Sankyo Company, Limited |
Inhibiteur de la mort des cellules nerveuses imputable à la cytotoxicité de l'acide glutamique
|
GB9909041D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB9909075D0
(en)
*
|
1999-04-20 |
1999-06-16 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
CO5170421A1
(es)
|
1999-04-23 |
2002-06-27 |
Smithkline Beecham Plc |
Nuevo compuesto farmaceutico maleico
|
US20040248945A1
(en)
|
1999-04-23 |
2004-12-09 |
Smithkline Beecham P.L.C. |
Thiazolidinedione derivative and its use as antidiabetic
|
AP1607A
(en)
*
|
1999-04-23 |
2006-05-03 |
Smithkline Beecham Plc |
Thiazolidinedione derivative and its use as antidiabetic.
|
DE60004658T2
(de)
|
1999-04-23 |
2004-06-24 |
Smithkline Beecham Plc, Brentford |
Thiazolidindionderivat und seine verwendung als antidiabetikum
|
EP1180520B1
(en)
|
1999-04-28 |
2007-06-20 |
Institute of Medicinal Molecular Design, Inc. |
Pyrimidine carboxylic acid derivatives
|
GB9913782D0
(en)
*
|
1999-06-14 |
1999-08-11 |
Smithkline Beecham Plc |
Novel compounds
|
CA2377246A1
(en)
*
|
1999-06-18 |
2000-12-28 |
Ranjit C. Desai |
Arylthiazolidinedione and aryloxazolidinedione derivatives
|
JP2001072592A
(ja)
|
1999-07-01 |
2001-03-21 |
Kyowa Hakko Kogyo Co Ltd |
テロメラーゼ阻害剤
|
AU7408900A
(en)
*
|
1999-08-17 |
2001-03-13 |
Smithkline Beecham Plc |
Pharmaceutical compositions containing thiazolidinedione derivatives and process for their preparation
|
US6878749B2
(en)
|
1999-09-17 |
2005-04-12 |
Novartis Ag |
Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
|
AR028299A1
(es)
|
1999-09-17 |
2003-05-07 |
Novartis Ag |
Una composicion farmaceutica que comprende nateglinida, un proceso para su preparacion y el uso de dicha composicion para la preparacion de un medicamento para el tratamiento de desordenes metabolicos, especialmente diabetes, o de una enfermedad o condicion asociada con diabetes.
|
US6559188B1
(en)
|
1999-09-17 |
2003-05-06 |
Novartis Ag |
Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
|
AR030920A1
(es)
*
|
1999-11-16 |
2003-09-03 |
Smithkline Beecham Plc |
Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
|
ES2156574B1
(es)
*
|
1999-11-18 |
2002-02-01 |
Vita Invest Sa |
Nuevos derivados de tiazolidindiona como agentes antidiabeticos
|
YU50302A
(sh)
|
1999-12-03 |
2006-01-16 |
Kyoto Pharmaceutical Industries Ltd. |
Nova heterociklična jedinjenja, njihove soli i njihova primena u medicini
|
HU225919B1
(en)
*
|
1999-12-18 |
2007-12-28 |
Richter Gedeon Nyrt |
Thiazolidine-derivatives, process for their preparation pharmaceutical and intermediates
|
US20030139434A1
(en)
|
2000-01-21 |
2003-07-24 |
Bork Balkan |
Combinations comprising dipeptidylpeptidase-iv inhibitor
|
GB0006133D0
(en)
*
|
2000-03-14 |
2000-05-03 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US6680387B2
(en)
|
2000-04-24 |
2004-01-20 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6784199B2
(en)
*
|
2000-09-21 |
2004-08-31 |
Aryx Therapeutics |
Isoxazolidine compounds useful in the treatment of diabetes, hyperlipidemia, and atherosclerosis in mammals
|
US6958355B2
(en)
|
2000-04-24 |
2005-10-25 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US6768008B2
(en)
|
2000-04-24 |
2004-07-27 |
Aryx Therapeutics |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
US20040115626A1
(en)
*
|
2000-05-25 |
2004-06-17 |
Masahide Goto |
Human pgc-1 promoter
|
GB0014005D0
(en)
*
|
2000-06-08 |
2000-08-02 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US7078397B2
(en)
|
2000-06-19 |
2006-07-18 |
Smithkline Beecham Corporation |
Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
GB0019223D0
(en)
*
|
2000-08-04 |
2000-09-27 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0019228D0
(en)
*
|
2000-08-04 |
2000-09-27 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0021865D0
(en)
*
|
2000-09-06 |
2000-10-18 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0021978D0
(en)
|
2000-09-07 |
2000-10-25 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US7241895B2
(en)
|
2000-09-26 |
2007-07-10 |
Dr. Reddy's Laboratories Limited |
Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
|
BR0114196A
(pt)
*
|
2000-09-26 |
2003-07-22 |
Reddy S Res Foundation |
Formas polimórficas de maleato de 5-[4-[2-[n-metil-n-(2-piridil) amino]etóxi]benzil]tiazolidina-2,4-diona e processo para a preparação das mesmas.
|
GB0023970D0
(en)
*
|
2000-09-29 |
2000-11-15 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0023971D0
(en)
*
|
2000-09-29 |
2000-11-15 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0029125D0
(en)
*
|
2000-11-29 |
2001-01-10 |
Specialistkliniken I Varberg H |
Novel treatment
|
US6452014B1
(en)
|
2000-12-22 |
2002-09-17 |
Geron Corporation |
Telomerase inhibitors and methods of their use
|
WO2002051839A1
(en)
|
2000-12-22 |
2002-07-04 |
Smithkline Beecham P.L.C. |
5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
|
ATE341343T1
(de)
*
|
2000-12-26 |
2006-10-15 |
Sankyo Co |
Medizinische zusammensetzungen mit diuretischem und die insulinresistenz verbesserndem mittel
|
WO2002051823A1
(en)
|
2000-12-26 |
2002-07-04 |
Torrent Pharmaceuticals Ltd |
Process for the preparation of rosiglitazone maleate
|
ES2174748B1
(es)
*
|
2001-01-31 |
2003-09-16 |
Vita Lab |
Nueva sal de tiazolidindiona y sus polimorfos como agentes antidiabeticos y procedimiento para la obtencion de los mismos.
|
ES2321815T3
(es)
*
|
2001-04-04 |
2009-06-12 |
Ortho-Mcneil-Janssen Pharmaceuticals, Inc. |
Combinacion terapeutica que comprende inhibidores de reabsorcion e glucosa y moduladores ppar.
|
US20060047000A1
(en)
*
|
2001-04-24 |
2006-03-02 |
Aryx Therapeutics, Inc. |
Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
|
ZA200309757B
(en)
*
|
2001-05-29 |
2004-12-22 |
Kyoto Pharma Ind |
Novel heterocyclic compound and medicinal use thereof.
|
HUP0400023A2
(hu)
*
|
2001-05-29 |
2004-04-28 |
Kyoto Pharmaceutical Industries, Ltd. |
Új heterociklusos származékok és gyógyászati alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
|
JP4152641B2
(ja)
*
|
2001-08-07 |
2008-09-17 |
クラシエ製薬株式会社 |
チアゾリジン誘導体の副作用軽減剤
|
WO2003029251A1
(en)
*
|
2001-09-28 |
2003-04-10 |
Biocon Limited |
Novel process for the synthesis of thiazolidinedione derivatives
|
GB0127805D0
(en)
*
|
2001-11-20 |
2002-01-09 |
Smithkline Beecham Plc |
Pharmaceutical composition
|
WO2003050112A1
(en)
*
|
2001-12-13 |
2003-06-19 |
Smithkline Beecham Plc |
Toluenesulfonate hydrates of a thiazolidinedione derivative
|
GB0129851D0
(en)
*
|
2001-12-13 |
2002-01-30 |
Smithkline Beecham Plc |
Novel compounds
|
GB0129876D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0129871D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0129872D0
(en)
*
|
2001-12-13 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
WO2003050116A1
(en)
*
|
2001-12-13 |
2003-06-19 |
Smithkline Beecham Plc |
A 5(-4-(2-(n-methyl-n-(2-pyridil)amino)ethoxy)benzyl)thiazolidine-2,4-dione (i) 10-camphorsulphonic acid salt and use against diabetes mellitus
|
AU2002352479A1
(en)
*
|
2001-12-20 |
2003-07-09 |
Smithkline Beecham Plc |
5- (4- (2- (n-methyl-n- (2-pyridyl) amino) ethoxy) benzyl) thiazolidine-2, 4-dione malic acid salt and use against diabetes mellitus
|
GB0130509D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0130511D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
GB0130510D0
(en)
*
|
2001-12-20 |
2002-02-06 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
US6992191B2
(en)
*
|
2001-12-20 |
2006-01-31 |
Teva Pharmaceutical Industries, Ltd. |
Hydrogenation of precursors to thiazolidinedione antihyperglycemics
|
US7015345B2
(en)
*
|
2002-02-21 |
2006-03-21 |
Asahi Kasei Pharma Corporation |
Propionic acid derivatives
|
KR100450700B1
(ko)
|
2002-03-22 |
2004-10-01 |
주식회사종근당 |
티아졸리딘디온 유도체 화합물 및 이를 함유하는 약제학적조성물
|
US20050119314A1
(en)
*
|
2002-04-05 |
2005-06-02 |
Sankyo Company, Limited |
Pharmaceutical composition comprising an ACAT inhibitor and an insulin resistance reducing agent
|
EP1474417B1
(en)
*
|
2002-04-29 |
2006-03-22 |
Teva Pharmaceutical Industries Ltd. |
Processes for preparing losartan and losartan potassium
|
US8216609B2
(en)
|
2002-08-05 |
2012-07-10 |
Torrent Pharmaceuticals Limited |
Modified release composition of highly soluble drugs
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
EP1388352A1
(en)
|
2002-08-08 |
2004-02-11 |
Laboratoires Fournier S.A. |
Use of a ppar-alpha agonist to treat patients suffering from weight gain associated with a ppar-gamma agonist treatment
|
CN1894234A
(zh)
|
2003-03-25 |
2007-01-10 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
WO2004089945A1
(en)
*
|
2003-04-09 |
2004-10-21 |
Ranbaxy Laboratories Limited |
Rosiglitazone derivatives as antidiabetic agents
|
US20050004179A1
(en)
*
|
2003-05-22 |
2005-01-06 |
Pedersen Ward A. |
Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
|
US7718377B2
(en)
*
|
2003-05-29 |
2010-05-18 |
Kyoto Pharmaceutical Industries, Ltd. |
Insulin resistance curative and method of screening the same
|
KR20060021870A
(ko)
*
|
2003-05-30 |
2006-03-08 |
랜박시 래보러터리스 리미티드 |
치환된 피롤 유도체와 hmg―co 억제제로서의 이의용도
|
FR2858556B1
(fr)
*
|
2003-08-06 |
2006-03-10 |
Galenix Innovations |
Composition pharmaceutique solide dispersible et/ou orodispersible non pelliculee contenant au moins le principe actif metformine, et procede de preparation
|
KR20060041309A
(ko)
|
2003-08-13 |
2006-05-11 |
다케다 야쿠힌 고교 가부시키가이샤 |
4-피리미돈 유도체 및 펩티딜 펩티다제 저해제로서의 그의용도
|
EP1699777B1
(en)
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
AU2003269483A1
(en)
*
|
2003-09-10 |
2005-03-29 |
Biocon Limited |
Phosphoric acid salt of 5-((4-(2-(methyl-2-pyridinylamino) ethoxy) phenyl) methyl)- 2,4-thiazolidinedione
|
JP5140881B2
(ja)
*
|
2003-09-17 |
2013-02-13 |
要 川杉 |
医薬組成物
|
US20050163842A1
(en)
*
|
2003-12-31 |
2005-07-28 |
Garth Boehm |
Rosiglitazone and metformin formulations
|
WO2005065654A2
(en)
*
|
2003-12-31 |
2005-07-21 |
Alpharma, Inc. |
Rosiglitazone formulations
|
EP1709038A2
(en)
*
|
2004-01-28 |
2006-10-11 |
Usv Limited |
A process for the preparation of 5- 4- 2- n-methyl -n-(2-pyridyl) amino ethoxy phenyl methyl thiaz olidine-2, 4-dione maleate
|
AR047541A1
(es)
*
|
2004-02-13 |
2006-01-25 |
Sandoz Ag |
Fosfato de 5-[[4-[2-metil-2-piridinil-amino-etoxi]fenil]metil]-2,4 tiazolidinadiona (rosiglitazona) y sus formas polimorficas
|
GB2410948A
(en)
*
|
2004-02-13 |
2005-08-17 |
Sandoz Ag |
Novel phosphoric acid salt of rosiglitazone
|
GB2421240A
(en)
*
|
2004-12-14 |
2006-06-21 |
Sandoz Ag |
Phosphoric acid salt of rosiglitazone
|
CN102134231B
(zh)
|
2004-03-15 |
2020-08-04 |
武田药品工业株式会社 |
二肽基肽酶抑制剂
|
BRPI0509305A
(pt)
*
|
2004-03-29 |
2007-09-04 |
Sankyo Co |
uso de um sensibilizador insulìnico, composição farmecêutica, e , kit
|
GB2413795A
(en)
*
|
2004-05-05 |
2005-11-09 |
Cipla Ltd |
Process for the preparation of rosiglitazone
|
CA2566352A1
(en)
*
|
2004-05-12 |
2005-11-17 |
Medichem S.A. |
Process for the preparation of rosiglitazone
|
CZ296468B6
(cs)
*
|
2004-06-10 |
2006-03-15 |
Zentiva, A. S. |
Sul kyseliny fosforecné s 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidin-2,4-dionema zpusob její prípravy
|
TW200608967A
(en)
*
|
2004-07-29 |
2006-03-16 |
Sankyo Co |
Pharmaceutical compositions containing with diabetic agent
|
CZ297266B6
(cs)
*
|
2004-09-10 |
2006-10-11 |
Zentiva, A. S. |
Zpusob prípravy rosiglitazonu
|
CZ297347B6
(cs)
*
|
2004-09-21 |
2006-11-15 |
Zentiva, A. S. |
Zpusob prípravy rosiglitazonu
|
US20060068010A1
(en)
*
|
2004-09-30 |
2006-03-30 |
Stephen Turner |
Method for improving the bioavailability of orally delivered therapeutics
|
US20060089387A1
(en)
*
|
2004-10-26 |
2006-04-27 |
Le Huang |
Stabilized pharmaceutical composition comprising antidiabetic agent
|
US20070190079A1
(en)
*
|
2004-10-29 |
2007-08-16 |
Kalypsys, Inc. |
Methods for the selective modulation of ppar
|
US20060122232A1
(en)
*
|
2004-12-06 |
2006-06-08 |
Development Center For Biotechnology |
4-Hydroxyfuroic acid derivatives
|
EP1828192B1
(en)
|
2004-12-21 |
2014-12-03 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
US20070269486A1
(en)
*
|
2005-03-14 |
2007-11-22 |
Conor Medsystems, Llc. |
Methods and Devices for Reducing Tissue Damage After Ischemic Injury
|
CZ298424B6
(cs)
*
|
2005-05-24 |
2007-09-26 |
Zentiva, A. S. |
Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
|
FR2887442A1
(fr)
*
|
2005-06-28 |
2006-12-29 |
Oreal |
Composes benzyl-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute
|
FR2887444A1
(fr)
*
|
2005-06-28 |
2006-12-29 |
Oreal |
Composes benzylidene-1,3-thiazolidine-2,4-diones, leurs utilisations et compositions pour stimuler ou induire la pousse des fibres keratiniques et/ou freiner leur chute et/ou augmenter leur densite.
|
CA2615118A1
(en)
*
|
2005-07-12 |
2007-01-18 |
Daiichi Sankyo Company, Limited |
Pharmaceutical composition containing ppar.gamma. agonist
|
ME02005B
(me)
*
|
2005-09-14 |
2012-08-31 |
Takeda Pharmaceuticals Co |
Inhibitori dipeptidil peptidaze za lečenje dijabetesa
|
EP1924567B1
(en)
*
|
2005-09-16 |
2012-08-22 |
Takeda Pharmaceutical Company Limited |
Process for the preparation of pyrimidinedione derivatives
|
TW200738266A
(en)
*
|
2005-09-29 |
2007-10-16 |
Sankyo Co |
Pharmaceutical agent containing insulin resistance improving agent
|
WO2007054896A1
(en)
*
|
2005-11-08 |
2007-05-18 |
Ranbaxy Laboratories Limited |
Process for (3r, 5r)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt
|
TW200730173A
(en)
*
|
2005-12-16 |
2007-08-16 |
Sankyo Co |
Pharmaceutical composition enhancing production of adiponectin
|
CA2645189A1
(en)
*
|
2006-03-08 |
2008-01-24 |
Medichem, S.A. |
Process for preparation of intermediates of rosiglitazone, rosiglitazone and new polymorphic forms thereof
|
US20070238716A1
(en)
*
|
2006-03-14 |
2007-10-11 |
Murthy Ayanampudi S R |
Statin stabilizing dosage formulations
|
EP1999108A1
(en)
*
|
2006-03-28 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
JP2009532372A
(ja)
*
|
2006-03-31 |
2009-09-10 |
ウェルスタット セラピューティクス コーポレイション |
代謝障害の併用治療
|
DE202006020710U1
(de)
|
2006-05-09 |
2009-12-31 |
Teva Pharmaceutical Industries Ltd. |
Zusammensetzungen mit Rosiglitazonmaleat
|
US7435741B2
(en)
*
|
2006-05-09 |
2008-10-14 |
Teva Pharmaceutical Industries, Ltd. |
2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate
|
US20070293546A1
(en)
*
|
2006-06-15 |
2007-12-20 |
Srinivasula Reddy Maddula |
Preparation of rosiglitazone and its salts
|
HUP0600517A3
(en)
*
|
2006-06-23 |
2008-10-28 |
Richter Gedeon Nyrt |
Process for the production of benzylidene-rosiglitazone base
|
WO2008002591A2
(en)
|
2006-06-26 |
2008-01-03 |
Amgen Inc |
Methods for treating atherosclerosis
|
WO2008010087A2
(en)
*
|
2006-07-14 |
2008-01-24 |
Ranbaxy Laboratories Limited |
Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
|
AU2007293885A1
(en)
|
2006-09-07 |
2008-03-13 |
Takeda Gmbh |
Combination treatment for diabetes mellitus
|
KR20090088854A
(ko)
*
|
2006-09-13 |
2009-08-20 |
다케다 야쿠힌 고교 가부시키가이샤 |
2-6-(3-아미노-피페리딘-엘-일)-3-메틸-2,4-디옥소-3,4-디하이드로-2h-피리미딘-1-일메틸-4-플루오로-벤조니트릴의 용도
|
US8324383B2
(en)
|
2006-09-13 |
2012-12-04 |
Takeda Pharmaceutical Company Limited |
Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
|
TW200838536A
(en)
*
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
JP2010513324A
(ja)
|
2006-12-21 |
2010-04-30 |
アルファファーム ピーティーワイ リミテッド |
医薬化合物および医薬組成物
|
WO2008091624A2
(en)
*
|
2007-01-22 |
2008-07-31 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of rosiglitazone hydrobromide and processes for preparation thereof
|
EP1988091B1
(en)
|
2007-02-07 |
2015-06-10 |
Kyowa Hakko Kirin Co., Ltd. |
Tricyclic compounds
|
US8093236B2
(en)
*
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
DK2068909T3
(da)
|
2007-03-30 |
2012-08-06 |
Ambrx Inc |
Modificerede FGF-21-polypeptider og anvendelse heraf
|
CN101679298B
(zh)
|
2007-04-05 |
2013-10-23 |
第一三共株式会社 |
稠合二环杂芳基衍生物
|
US20080249156A1
(en)
*
|
2007-04-09 |
2008-10-09 |
Palepu Nageswara R |
Combinations of statins and anti-obesity agent and glitazones
|
AU2008261102B2
(en)
|
2007-06-04 |
2013-11-28 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
MY159075A
(en)
|
2007-07-26 |
2016-12-15 |
Amgen Inc |
Modified lecithin-cholesterol acyltransferase enzymes
|
US20090076093A1
(en)
*
|
2007-09-14 |
2009-03-19 |
Protia, Llc |
Deuterium-enriched rosiglitazone
|
PL384446A1
(pl)
*
|
2008-02-12 |
2009-08-17 |
Adamed Spółka Z Ograniczoną Odpowiedzialnością |
Sól 5-[[4-[2-(metylo-2-pirydynyloamino)etoksy]fenylo]metylo]-2,4-tiazolidynodionu z kwasem malonowym i sposób jej wytwarzania
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
JP5559689B2
(ja)
|
2008-08-06 |
2014-07-23 |
協和発酵キリン株式会社 |
3環系化合物
|
US8846315B2
(en)
|
2008-08-12 |
2014-09-30 |
Zinfandel Pharmaceuticals, Inc. |
Disease risk factors and methods of use
|
NZ710443A
(en)
|
2008-08-12 |
2019-03-29 |
Zinfandel Pharmaceuticals Inc |
Method of identifying disease risk factors
|
EP2184055A1
(en)
|
2008-11-07 |
2010-05-12 |
LEK Pharmaceuticals d.d. |
Process for preparing solid dosage forms of rosiglitazone maleate
|
US20100144140A1
(en)
*
|
2008-12-10 |
2010-06-10 |
Novellus Systems, Inc. |
Methods for depositing tungsten films having low resistivity for gapfill applications
|
HUP0800755A2
(en)
|
2008-12-11 |
2010-09-28 |
Richter Gedeon Nyrt |
Crystalline forms of rosiglitazone
|
RU2480463C1
(ru)
|
2009-03-05 |
2013-04-27 |
Дайити Санкио Компани, Лимитед |
Пиридилокси производные, полезные в качестве активатора/модулятора гамма-рецептора, активируемого пролифератором пероксисом (ppar) гамма
|
DE102009053562A1
(de)
|
2009-11-18 |
2011-05-19 |
Alfred E. Tiefenbacher (Gmbh & Co. Kg) |
Rosiglitazonsuccinat enthaltende pharmazeutische Zusammensetzung
|
JP2013523681A
(ja)
|
2010-03-30 |
2013-06-17 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Sglt2インヒビター及びppar−ガンマアゴニストを含む医薬組成物並びにその使用
|
CA2810361A1
(en)
|
2010-09-07 |
2012-03-15 |
Daiichi Sankyo Company, Limited |
Process for preparing benzoic acid esters
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
US20120094959A1
(en)
|
2010-10-19 |
2012-04-19 |
Bonnie Blazer-Yost |
Treatment of cystic diseases
|
KR20180050420A
(ko)
|
2011-01-10 |
2018-05-14 |
진판델 파마슈티컬스 인코포레이티드 |
알츠하이머 병 치료를 위한 방법 및 약품
|
WO2013018899A1
(ja)
|
2011-08-03 |
2013-02-07 |
協和発酵キリン株式会社 |
ジベンゾオキセピン誘導体
|
WO2013068486A1
(en)
|
2011-11-08 |
2013-05-16 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the diagnosis and treatment of male infertility
|
WO2013086443A1
(en)
|
2011-12-08 |
2013-06-13 |
Amgen Inc. |
Agonistic human lcat antigen binding proteins and their use in therapy
|
US9504679B2
(en)
|
2011-12-19 |
2016-11-29 |
Bjoern Colin Kahrs |
Pharmaceutical compositions comprising glitazones and Nrf2 activators
|
US20130158077A1
(en)
|
2011-12-19 |
2013-06-20 |
Ares Trading S.A. |
Pharmaceutical compositions
|
CA2890086C
(en)
|
2012-11-05 |
2022-05-31 |
Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) |
Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
|
AU2014235209B2
(en)
|
2013-03-15 |
2018-06-14 |
Bausch Health Ireland Limited |
Guanylate cyclase receptor agonists combined with other drugs
|
WO2014151206A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
WO2015054500A2
(en)
|
2013-10-09 |
2015-04-16 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines
|
CA2928725A1
(en)
|
2013-11-05 |
2015-05-14 |
Esther Priel |
Compounds for the treatment of diabetes and disease complications arising from same
|
EA036697B1
(ru)
|
2014-10-24 |
2020-12-09 |
Бристол-Майерс Сквибб Компани |
Модифицированные полипептиды fgf-21 и их применение
|
US10034868B2
(en)
|
2014-11-04 |
2018-07-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and the treatment of rapidly progressive glomerulonephritis
|
EP3568134A1
(en)
|
2017-01-16 |
2019-11-20 |
Institut National de la Sante et de la Recherche Medicale (INSERM) |
Methods and pharmaceutical compositions for reducing cd95- mediated cell motility
|
GR1010570B
(el)
*
|
2022-12-22 |
2023-11-17 |
Uni-Pharma Κλεων Τσετης Φαρμακευτικα Εργαστηρια Α.Β.Ε.Ε., |
4-(2-(4-((2,4-διοξοθειαζολιδιν-5-υλ)μεθυλ)φαινοξυ) παραγωγα με δραση αναστολης της αυτοταξινης
|